Allworth Financial’s Akebia Therapeutics AKBA Stock Holding History

Allworth Financial’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.36K	Buy	3,135 +2,325	+287%	+$3.19K	﹤0.01%	4038
2025 Q4	$1.3K	Buy	810 +51	+7%	+$107	﹤0.01%	4275
2025 Q3	$2.07K	Buy	759 +11	+1%	+$37	﹤0.01%	3984
2025 Q2	$2.72K	Hold	748	–	–	﹤0.01%	3571
2025 Q1	$1.71K	Hold	748	–	–	﹤0.01%	3268
2024 Q4	$1.79K	Hold	748	–	–	﹤0.01%	3190
2024 Q3	$988	Hold	748	–	–	﹤0.01%	3220
2024 Q2	$1.01K	Hold	748	–	–	﹤0.01%	3155
2024 Q1	$1.37K	Hold	748	–	–	﹤0.01%	2968
2023 Q4	$928	Hold	748	–	–	﹤0.01%	2971
2023 Q3	$853	Hold	748	–	–	﹤0.01%	2897
2023 Q2	$685	Hold	748	–	–	﹤0.01%	2831
2023 Q1	$420	Hold	748	–	–	﹤0.01%	2873
2022 Q4	$432	Buy	+748	New	+$234	﹤0.01%	2671
2021 Q1	–	Sell	-748	Closed	-$2K	–	1474
2020 Q4	$2K	Hold	748	–	–	﹤0.01%	1125
2020 Q3	$2K	Hold	748	–	–	﹤0.01%	966
2020 Q2	$10K	Hold	748	–	–	﹤0.01%	716
2020 Q1	$6K	Hold	748	–	–	﹤0.01%	815
2019 Q4	$5K	Hold	748	–	–	﹤0.01%	753
2019 Q3	$3K	Hold	748	–	–	﹤0.01%	745
2019 Q2	$4K	Hold	748	–	–	﹤0.01%	694
2019 Q1	$6K	Hold	748	–	–	﹤0.01%	637
2018 Q4	$4K	Buy	+748	New	+$5.85K	﹤0.01%	631

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Allworth Financial's AKBA Position: Q1 2026 in Review

Allworth Financial increased its Akebia Therapeutics (AKBA) stake by 287% in Q1 2026, buying an estimated $3.19K and bringing the position to 3,135 shares worth $4.36K. The position accounts for ﹤0.01% of the portfolio, ranked #4038.

Allworth Financial first reported a position in AKBA in Q4 2018 and has held it in 23 quarters since. The position peaked at $10K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Allworth Financial held 3,135 shares of Akebia Therapeutics worth $4.36K as of Q1 2026.
Allworth Financial bought 2,325 Akebia Therapeutics shares in Q1 2026, an estimated $3.19K.
Akebia Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4038 holding.
Allworth Financial first reported a position in Akebia Therapeutics in Q4 2018 and has held it in 23 quarters since.
Allworth Financial's Akebia Therapeutics position peaked at $10K in Q2 2020.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.